Kocefan (Ceftriaxone Disodium Salt Hemiheptahydrate)

Ceftriaxone inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins. This blocks the final cross‑linking step of peptidoglycan formation, leading to weakened cell walls, osmotic instability, and ultimately bacterial lysis. The mechanism provides broad activity against many Gram‑negative and some Gram‑positive organisms.

The dose of Kocefan is individualized by the prescribing clinician based on the type and severity of infection, patient weight, age, renal and hepatic function, and local resistance patterns. The prescriber determines the appropriate amount, frequency, and duration of therapy.

Safety data for ceftriaxone in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Kocefan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.

Compared with earlier‑generation cephalosporins, ceftriaxone offers a broader spectrum against Gram‑negative organisms and a longer half‑life, allowing once‑daily dosing. Unlike many penicillins, it is more resistant to beta‑lactamase degradation, making it effective for infections where resistance to penicillins is common.

Kocefan must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before use, allow the product to reach room temperature if required, and follow aseptic technique when reconstituting or drawing up the injectable solution.

Kocefan is supplied as an injectable solution for intramuscular injection. The vial is typically reconstituted with a compatible diluent, inspected for particulates, and administered by a qualified healthcare professional using aseptic technique. The injection site should be rotated to minimize local irritation.

Serious adverse events include anaphylactic reactions, Clostridioides difficile‑associated colitis, severe hepatic injury, and hemolytic anemia. Additionally, precipitation can occur if ceftriaxone is mixed with calcium‑containing solutions, especially in neonates, leading to potentially fatal complications.

Kocefan is contraindicated in patients with a known hypersensitivity to ceftriaxone, other cephalosporins, or penicillins. Neonates (≤28 days) receiving calcium‑containing intravenous fluids should not receive ceftriaxone due to the risk of fatal precipitation. Caution is also advised in patients with severe renal or hepatic impairment.